Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11319539 Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

Patent 11319539 was granted and assigned to Alnylam Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity

The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting a xanthine dehydrogenase (XDH) gene, and methods of using such double stranded RNAi agents to inhibit expression of an XDH gene and methods of treating subjects having an XDH-associated disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11319539 Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo